This federal contract award is for the supply of Tyvaso (treprostinil) inhalation solution to the U.S. Department of Veterans Affairs (VA). The $186,978.50 firm-fixed-price contract was awarded to United Therapeutics Corp, a self-certified small disadvantaged business and manufacturer of pharmaceutical goods.
The contract is a Blanket Purchase Agreement (BPA) call order under United Therapeutics' $50 million BPA with the VA National Acquisition Center, which enables the VA to efficiently procure the company's pulmonary arterial hypertension and oncology drug portfolio. United Therapeutics also holds a $198 million Federal Supply Schedule contract with the VA for Pharmaceuticals and Drugs, further facilitating the agency's centralized procurement of the company's medication products.
This contract award does not have a set-aside designation, as it is a commercial item procurement. United Therapeutics serves as the prime contractor without any subcontractors. The contract has an ultimate completion date of March 31, 2022 and was awarded on December 23, 2020.
Generated 12/6/24, 9:23 AM